About Us

Daniel M. Skovronsky
Daniel M. Skovronsky , M.D., Ph.D., Founder and CEO

Dr. Skovronsky founded Avid Radiopharmaceuticals in late 2004. Dr. Skovronsky has more than 20 peer-reviewed publications and two NIH-funded grants on Alzheimer’s disease research. Prior to establishing Avid, Dr. Skovronsky served as Scientific Director of High Throughput Screening and Drug Discovery at the Center for Neurodegenerative Disease Research at the University of Pennsylvania. Dr. Skovronsky trained as a resident in Pathology and completed a fellowship in Neuropathology at the Hospital of the University of Pennsylvania. Dr. Skovronsky received his M.D. and Ph.D. from the University of Pennsylvania and did his undergraduate training in molecular biochemistry at Yale University. Dr. Skovronsky is the recipient of numerous scientific and business awards and was recently named by the Philadelphia Business Journal as one of their “Forty under Forty” business leaders in the region. Dr. Skovronsky recently received the Ernst & Young Entrepreneur Of The Year® 2009 Award in the Emerging Company category in Greater Philadelphia, which recognizes outstanding entrepreneurs who are building and leading dynamic, growing businesses.

Michael Pontecorvo
Michael J. Pontecorvo, Ph.D., Vice President, Clinical Development

Dr. Pontecorvo is a recognized expert in Alzheimer's disease research and led the U.S. development of the Alzheimer's disease medication REMINYL® (now known as RAZADYNE®). Dr. Pontecorvo brings Avid almost 25 years of pharmaceutical industry experience in both CNS discovery research and clinical development. Over the past 15 years, Dr. Pontecorvo has held increasingly responsible positions in clinical development as a project leader at Janssen Pharmaceutica and as Vice President for Clinical Research at Mitsubishi Pharma America and Dov Pharmaceuticals. Author of more than 30 publications, numerous invited presentations, and six patents, Dr. Pontecorvo graduated from Indiana University with a Ph.D. in Psychology and Neuroscience.

John Lister-James
John Lister-James, Ph.D., Vice President, Chemical Development and Manufacturing

Dr. Lister-James brings to Avid over 20 years of experience in research and development in the pharmaceutical industry, principally in the area of radiopharmaceuticals, having held management and senior management positions at Centocor, Diatide, Berlex/Schering AG, CIS-US and Xanthus.

Dr. Lister-James directed CMC Development leading to the regulatory approval of three diagnostic radiopharmaceutical products and played a key role in the R&D activities leading to the discovery and early development of multiple radiodiagnostic and radiotherapeutic products.

Most recently Dr. Lister-James held the position of Vice President, Development at Xanthus Pharmaceuticals, a specialty company, and he was previously responsible for Corporate CMC Development, Radiopharmaceuticals in Schering AG.

Dr. Lister-James received his Ph.D. in Organic Chemistry from the University of London and did his post-doctoral work at MIT and Harvard Medical School on the chemistry of technetium and its application in medical imaging. He is a co-inventor of 60 U.S. patents and has co-authored over 35 peer-reviewed articles.

Mark A. Mintun
Mark A. Mintun, M.D., Chief Medical Officer

Dr. Mintun joined Avid from Washington University School of Medicine where he was Professor of Radiology at the Mallinckrodt Institute of Radiology, with joint appointments in Psychiatry, Bioengineering, and the Anatomy and Neurobiology Departments. He earned a Bachelor of Science in Chemical Engineering from the Massachusetts Institute of Technology in 1977. He received his medical degree in 1981 and completed a research fellowship in neurology and residency training in nuclear medicine at Washington University School of Medicine. Dr. Mintun has been extensively involved in investigating the nature of flow and metabolism changes in the human activated brain. His scientific contributions date back to seminal work in the development of functional imaging with PET. He developed the first compartment model analysis of PET radioligand data and defined terms, such as Binding Potential, that are still being used for describing in vivo PET radioligand binding. Other contributions include a method for measuring regional oxygen metabolism with PET and the first method to average functional brain images in a standard atlas coordinate system.

In addition to his own NIH-funded research projects in brain metabolism, he was Director of the Center for Clinical Imaging Research, Principal Investigator of the NINDS Center Core for Brain Imaging, and Director of the Neuroimaging Core of the Human Aging and Senile Dementia Program Project with Washington University’s Alzheimer’s Disease Research Center.